BioMarin Receives Positive CHMP Opinion in Europe to Expand Use of VOXZOGO® (vosoritide) to Treat Children Aged 4 Months and Older with Achondroplasia

European Commission Approval Decision Expected Q4 2023

Opinion Based on Positive Results from Global Phase 2 and Ongoing Extension Study 

U.S. Food and Drug Administration PDUFA Target Action Date for Supplemental New Drug Application for VOXZOGO for Children Under 5 is Oct. 21, 2023

Read more at prnewswire.com